National Institutes of Health

Description

-Purpose. This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites applications for research projects that investigate the effects of Erythropoietin (EPO) on tumor cell growth. EPO has been widely used to relieve the anemia associated with renal failure. In addition, EPO and other erythropoiesis stimulating agents (ESAs) have recently been used to treat the anemia associated with cancer chemotherapy. However, several clinical trials involving administration of ESAs, have suggested that ESAs may accelerate tumor progression and increase mortality in cancer patients. It is therefore important to understand the biology of ESAs on tumor cell growth and apoptosis. The purpose of this FOA is to stimulate high quality research on the effects of ESAs on tumor cell biology and tumor progression. -Mechanism of Support. This FOA utilizes the NIH Exploratory/Developmental Grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-023 that encourages applications under the NIH Research Project Grant (R01) mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV